GlySens Discusses its Long Term Fully Implantable Glucose Monitoring System at NIH Artificial Pancreas Conference
BETHESDA, MD – April 10, 2013 - GLYSENS INCORPORATED’S presentation entitled “Long Term, Fully-Implanted, Self-Contained Subcutaneous Glucose Sensor: Results from Clinical Evaluation and Applicability for Closed Loop Systems” was delivered today by Dr. Joseph Lucisano, the Company’s president and CEO, at the “Workshop on Innovation towards an Artificial Pancreas,” held at the National Institutes of Health (NIH). The April 9-10 workshop, co-sponsored by the NIH, the U.S. Food and Drug Administration (FDA), and the Juvenile Diabetes Research Foundation (JDRF), is bringing...Read More>
GlySens Presents Results of Human Feasibility Study at the Annual Diabetes Technology Meeting
BURLINGAME, CA - November 8, 2012 - GLYSENS INCORPORATED presented results today of the recently completed first human feasibility trial of its long term, fully implantable continuous glucose monitoring (ICGM) system. The trial evaluated the Company’s first generation fully-implanted sensors in six individuals with diabetes for periods of five to six months. The presentation, entitled “Application of the Implantable Continuous Glucose Monitoring System in a Human Subject” was delivered by GlySens’s President and CEO Dr. Joseph Lucisano at a morning session of the...Read More>
West Health Investment Fund invests in GlySens
August 12, 2012 - West Health Investment Fund invests in GlySens and RxAnte Startups demonstrate innovative technologies to lower the cost of health care in the treatment of diabetes and medication adherence SAN DIEGO, CA. – Sept. 12, 2012 – The West Health Investment Fund, West Health’s fund focused on lowering health care costs, has announced it participated in the recent venture financings of GlySens, Inc. and RxAnte, Inc., two startup technology companies with innovative technologies that could lower the cost of health care. Financial terms of the investments were not disclosed. “Through targeted external investments in companies focused in advancing cost-effective and cost-saving models of care,... Read More>
GlySens Incorporated featured in Scientific American
SAN DIEGO, CA - May 1, 2012 - GLYSENS INCORPORATED is featured in the May 2012 issue of Scientific American, in an article entitled “Smart Implantable Devices”. In the article, author Katherine Harmon reports: “A new implantable glucose sensor made by GlySens in San Diego might someday offer millions of diabetics a wireless monitoring system of their own. The device takes near-continuous readings under the skin of a patient’s glucose level- which is then correlated to the level in the blood. The result: far more accurate and more complete information for guiding insulin dosing and timing than can be achieved by testing blood from finger pricks. And because the sensor is implanted, it requires less upkeep than current external monitors.”Read More>
GlySens Incorporated profiled by the San Diego Union-Tribune
SAN DIEGO, CA - July 29, 2010 - GLYSENS INCORPORATED is profiled in a front-page story in today’s San Diego Union-Tribune by Staff Writer Keith Darcé, entitled, “SD company hopes monitor will revolutionize diabetes care.”Read More>
A small San Diego medical device company and a UCSD scientist believe they’ve come up with the solution to a problem that has long vexed people with diabetes: a device that constantly monitors blood-sugar levels without painful finger pricks or frequent maintenance.
GlySens is seeking permission from the Food and Drug Administration to launch a pilot study testing its implanted wireless sensor in about a dozen people with diabetes. The request came after researchers completed trials of the device on animals.
On Wednesday, University of California San Diego bioengineering professor David Gough and several GlySens researchers published results from the final study on a pair of pigs in the journal Science Translational Medicine.